Atherosclerosis and systemic lupus erythematosus: the role of altered lipids and of autoantibodies

Abstract

The accelerated atherosclerosis that occurs in some patients with systemic lupus erythematosus (SLE) has a complex pathogenesis, including alterations in lipids, inflammation and the immune system. In this article, we review the evidence that peroxidase-related alteration of normal, protective high-density lipoprotein (HDL) converts them to pro-inflammatory HDL (piHDL), characterized by lower content of the cholesterol transport lipoprotein ApoA1 and impaired function of the antioxidant enzyme paroxonase, which prevents oxidation of low-density lipoprotein (LDL). Forty-five per cent of women with SLE have piHDL compared with 20% of patients with rheumatoid arthritis and 4% of healthy controls. The presence of piHDL increases risk for coronary artery events and carotid artery plaque. Another result of lipid oxidation in patients with SLE is generation of highly oxidized LDL and phospholipids (PL), probably stimulating antibodies to OxPL phospholipids. These antibodies along with promoting thrombosis also interfere with deposits of Annexin V onto endothelial cells, which probably promote increased instability of atherosclerotic plaque. Thus, piHDL and anti-OxPL promote plaque formation, plaque instability and thrombosis, accounting for some of the large increase in atherosclerosis and coronary artery events in SLE.

Get full access to this article

View all access options for this article.

References

1 McMahon M Hahn BH . Atherosclerosis and systemic lupus erythematosus – mechanistic basis of the association. Curr Opin Immunol 2007; 19: 633 – 639 .

2 Roman JM Shanker BA Davis A . Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399 – 2406 .

3 Frostegard J Svenungsson E Wu R . Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 2005; 52: 192 – 200 .

4 McMahon M Grossman J FitzGerald J . Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54: 2541 – 2549 .

5 McMahon M Grossman J FitzGerald J . The novel biomarker pro-inflammatory HDL is associated with carotid artery plaque in women with SLE. Arthritis Rheum 2006; 54: S522 [abstract].

6 Su J Gorgiades A Wu R Thulin T De Faire U Forstegard J . Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 2006; 188: 160 – 166 .

7 Feng X Li H Rumbin AA . ApoE−/−Fas−/−C57Bl/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis and osteopenia. J Lipid Res 2007; 48: 794 – 805 .

8 Cedarholm A Svenungsson E Jensen-Urstad K . Decreased binding of annexin V to endothelial cells: a potential mechanisms of atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2005; 198 – 203 .

9 Cedarholm A Frostegard J . Annexin A5 as a novel player in prevention of atherothrombosis in SLE and the general population. Ann NY Acad Sci 2007; 1108: 96 – 103 .